Topical corticosteroids for mycosis fungoides. Experience in 79 patients - PubMed (original) (raw)
Comparative Study
. 1998 Aug;134(8):949-54.
doi: 10.1001/archderm.134.8.949.
Affiliations
- PMID: 9722724
- DOI: 10.1001/archderm.134.8.949
Comparative Study
Topical corticosteroids for mycosis fungoides. Experience in 79 patients
H S Zackheim et al. Arch Dermatol. 1998 Aug.
Abstract
Objective: To determine the effectiveness of topical corticosteroids in the management of mycosis fungoides.
Design: Prospective study.
Setting: Academic referral center, Veterans Affairs Medical Center, and private practice.
Patients: Seventy-nine patients with patch or plaque stage of mycosis fungoides. Fifty-one were stage T1 (less than 10% of skin involved) and 28 were stage T2 (10% or more of skin involved). Seventy-five had patch-stage and 4 had plaque-stage disease as determined by histological examination.
Intervention: Patients were treated with topical class I to III corticosteroids. Of the stage T1 patients, all used class I corticosteroids, and 4 (8%) also used class II or III corticosteroids. Of the stage T2 patients, 19 (68%) used class I and 12 (43%) used class II or III compounds. Some patients used more than 1 class of corticosteroid. Applications were almost always twice daily. Three stage T1 and 2 stage T2 patients used plastic film occlusion. Baseline and monthly morning serum cortisol levels were obtained during treatment.
Main outcome measures: Response to treatment and side effects.
Results: The median follow-up period was 9 months. Thirty-two (63%) of stage T1 patients achieved complete remission and 16 (31%) achieved partial remission, for a total response rate of 48 (94%). The comparable figures for stage T2 patients were 7 (25%), 16 (57%), and 23 (82%), respectively. Responses were determined by clinical examination. Thirty-nine patients achieved clinical clearing. In 7 of these, posttreatment biopsy specimens were obtained, and all showed histological clearing. Reversible depression of serum cortisol levels occurred in 10 (13%). Minor skin irritation occurred in 2 patients and localized, reversible skin atrophy in 1.
Conclusion: Topical corticosteroids, especially class I compounds, are an effective treatment for patch-stage mycosis fungoides.
Comment in
- A challenging question regarding the use of topical corticosteroids for mycosis fungoides.
Rosenthal D. Rosenthal D. Arch Dermatol. 1998 Aug;134(8):1033-4. doi: 10.1001/archderm.134.8.1033. Arch Dermatol. 1998. PMID: 9722741 No abstract available.
Similar articles
- Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH, Martinez G, Varghese A, Hoppe RT. Kim YH, et al. Arch Dermatol. 2003 Feb;139(2):165-73. doi: 10.1001/archderm.139.2.165. Arch Dermatol. 2003. PMID: 12588222 - Treatment of patch-stage mycosis fungoides with topical corticosteroids.
Zackheim HS. Zackheim HS. Dermatol Ther. 2003;16(4):283-7. doi: 10.1111/j.1396-0296.2003.01639.x. Dermatol Ther. 2003. PMID: 14686970 Review. - Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
de Quatrebarbes J, Estève E, Bagot M, Bernard P, Beylot-Barry M, Delaunay M, D'Incan M, Souteyrand P, Vaillant L, Cordel N, Courville P, Joly P. de Quatrebarbes J, et al. Arch Dermatol. 2005 Sep;141(9):1117-20. doi: 10.1001/archderm.141.9.1117. Arch Dermatol. 2005. PMID: 16172308 Clinical Trial. - A challenging question regarding the use of topical corticosteroids for mycosis fungoides.
Rosenthal D. Rosenthal D. Arch Dermatol. 1998 Aug;134(8):1033-4. doi: 10.1001/archderm.134.8.1033. Arch Dermatol. 1998. PMID: 9722741 No abstract available. - Topical carmustine (BCNU) in the treatment of mycosis fungoides.
Zackheim HS. Zackheim HS. Dermatol Ther. 2003;16(4):299-302. doi: 10.1111/j.1396-0296.2003.01641.x. Dermatol Ther. 2003. PMID: 14686972 Review.
Cited by
- Hypopigmented mycosis fungoides in type v skin: a report of 5 cases.
Ranawaka RR, Abeygunasekara PH, de Silva MV. Ranawaka RR, et al. Case Rep Dermatol Med. 2011;2011:190572. doi: 10.1155/2011/190572. Epub 2011 Dec 20. Case Rep Dermatol Med. 2011. PMID: 23198169 Free PMC article. - Skin Directed Therapy in Cutaneous T-Cell Lymphoma.
Tarabadkar ES, Shinohara MM. Tarabadkar ES, et al. Front Oncol. 2019 Apr 11;9:260. doi: 10.3389/fonc.2019.00260. eCollection 2019. Front Oncol. 2019. PMID: 31032224 Free PMC article. Review. - Diagnosis of Early Mycosis Fungoides.
Miyagaki T. Miyagaki T. Diagnostics (Basel). 2021 Sep 19;11(9):1721. doi: 10.3390/diagnostics11091721. Diagnostics (Basel). 2021. PMID: 34574062 Free PMC article. Review. - Topical corticosteroid-induced skin atrophy: a comprehensive review.
Barnes L, Kaya G, Rollason V. Barnes L, et al. Drug Saf. 2015 May;38(5):493-509. doi: 10.1007/s40264-015-0287-7. Drug Saf. 2015. PMID: 25862024 Review. - Current and emerging treatment strategies for cutaneous T-cell lymphoma.
Lansigan F, Foss FM. Lansigan F, et al. Drugs. 2010 Feb 12;70(3):273-86. doi: 10.2165/11532190-000000000-00000. Drugs. 2010. PMID: 20166766 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical